Takeaways From FTC's Challenge Of Amgen Deal
The Federal Trade Commission's move this week to block Amgen Inc.'s proposed $27.8 billion purchase of Horizon Therapeutics PLC shows an aggressive attack by enforcers on a transaction that may not...To view the full article, register now.
Already a subscriber? Click here to view full article